Cabozantinib Gets Green Light
Exelixis' Cabometyx (cabozantinib) approved to treat kidney cancer
The US Food and Drug Administration (FDA) has approved a new treatment for advanced kidney cancer.
That new treatment is Exelixis' Cabometyx (cabozantinib). It has been approved to treat advanced renal cell carcinoma (RCC) — otherwise known as kidney cancer — for those who have already received certain medications to treat cancer.
Cabozantinib, under the brand name Cometriq, is already approved to treat thyroid cancer that has spread to other parts of the body.
A study of Cabometyx found that it appeared to delay the progression of cancer and increase overall survival.
Cabometyx is available in tablet form. The recommended dosing schedule is once a day.
Common side effects included diarrhea, fatigue, nausea and decreased appetite.
All information on this site is provided “as-is” for informational purposes only and is not a substitute for medical advice or treatment. You should consult with a medical professional if you have any questions about your health.
More health news
Health NewsFDA approves Cometriq to treat rare type of thyroid cancer
Cometriq to treat metastatic medullary thyroid cancer
Prescription DrugsFDA Approves New Rx For Rare Cancer
Cometriq approved to treat advanced medullary thyroid cancer
Prescription DrugsNew Kidney Cancer Rx Outperformed Standard Treatment
Cabozantinib for kidney cancer appeared more effective than everolimus (Afinitor)